Current translational and clinical practices in hematopoietic cell and gene therapy
- PMID: 22799276
- PMCID: PMC3655758
- DOI: 10.3109/14653249.2012.694420
Current translational and clinical practices in hematopoietic cell and gene therapy
Abstract
Clinical trials over the last 15 years have demonstrated that cell and gene therapies for cancer, monogenic and infectious disease are feasible and can lead to long-term benefit for patients. However, these trials have been limited to proof-of-principle and were conducted on modest numbers of patients or over long periods of time. In order for these studies to move towards standard practice and commercialization, scalable technologies for the isolation, ex vivo manipulation and delivery of these cells to patients must be developed. Additionally, regulatory strategies and clinical protocols for the collection, creation and delivery of cell products must be generated. In this article we review recent progress in hematopoietic cell and gene therapy, describe some of the current issues facing the field and discuss clinical, technical and regulatory approaches used to navigate the road to product development.
Similar articles
-
Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial.Biochem Pharmacol. 2020 Apr;174:113711. doi: 10.1016/j.bcp.2019.113711. Epub 2019 Nov 11. Biochem Pharmacol. 2020. PMID: 31726047 Review.
-
The Landscape of Cell and Gene Therapies for Solid Tumors.Cancer Cell. 2021 Jan 11;39(1):7-8. doi: 10.1016/j.ccell.2020.12.005. Cancer Cell. 2021. PMID: 33434513 No abstract available.
-
Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.Front Immunol. 2020 Aug 7;11:1965. doi: 10.3389/fimmu.2020.01965. eCollection 2020. Front Immunol. 2020. PMID: 32903482 Free PMC article. Review.
-
Ex vivo expansion of hematopoietic cells and their clinical use.Haematologica. 1998 Sep;83(9):824-48. Haematologica. 1998. PMID: 9825579 Review.
-
Ex vivo manipulation of cell subsets for cell therapies.Artif Organs. 1996 May;20(5):396-402. doi: 10.1111/j.1525-1594.1996.tb04522.x. Artif Organs. 1996. PMID: 8725617 Review.
Cited by
-
Practical considerations in gene therapy for HIV cure.Curr HIV/AIDS Rep. 2014 Mar;11(1):11-9. doi: 10.1007/s11904-013-0197-1. Curr HIV/AIDS Rep. 2014. PMID: 24449226 Free PMC article. Review.
-
Lymph nodes may be a source for immunetherapy in gastric cancer.Oncotarget. 2020 May 12;11(19):1729-1736. doi: 10.18632/oncotarget.27578. eCollection 2020 May 12. Oncotarget. 2020. PMID: 32477462 Free PMC article.
-
Clinical manufacturing of CAR T cells: foundation of a promising therapy.Mol Ther Oncolytics. 2016 Jun 15;3:16015. doi: 10.1038/mto.2016.15. eCollection 2016. Mol Ther Oncolytics. 2016. PMID: 27347557 Free PMC article. Review.
References
-
- Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet. 2011;12(5):301–15. Epub 2011/03/30. - PubMed
-
- Drolet BC, Lorenzi NM. Translational research: understanding the continuum from bench to bedside. Translational research : the journal of laboratory and clinical medicine. 2011;157(1):1–5. Epub 2010/12/15. - PubMed
-
- Zerhouni EA. Clinical research at a crossroads: the NIH roadmap. Journal of investigative medicine: the official publication of the American Federation for Clinical Research. 2006;54(4):171–3. Epub 2006/12/13. - PubMed
-
- Westfall JM, Mold J, Fagnan L. Practice-based research--“Blue Highways” on the NIH roadmap. JAMA : the journal of the American Medical Association. 2007;297(4):403–6. Epub 2007/01/25. - PubMed
-
- Silvestri F, Banavali S, Baccarani M, Preisler HD. The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications. Haematologica. 1992;77(3):265–73. Epub 1992/05/01. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical